Patients with RRMM who had received at least two lines of prior therapy including both an immunomodulatory agent and a PI, or at least three lines of anti-myeloma treatments including at least one of a PI, an immunomodulatory agent, or an anti-CD38 monoclonal antibody were more focused on increasing efficacy, with less importance placed on reducing the risk of specific side effects. This evidence concerns the gene CD38 and plasma cell myeloma.